Prescription Medicine

BioMarin Pharmaceutical Inc. paid $15 million upfront — and could pay an additional $43.5 million — for privately held Huxley Pharmaceuticals Inc., which has rights to a treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome. (BMRN)

A Gilead Sciences Inc. investigational antibiotic for cystic fibrosis patients with deadly infections will be reviewed by an FDA panel Dec. 10. (GILD)

Crystal Hayling, president and CEO of the Blue Shield of California Foundation, is leaving the nonprofit organization at year-end, after five years at the helm, officials told the San Francisco Business Times.

Acquisitions and more internal growth helped lift Hanger Orthopedic sales and profits. The company also raised its full-year earnings forecast. (HGR)

The Fred Hutchinson Cancer Research Center said it’s received a $500,000 grant that will be used to build the first American cancer clinic and training facility in Africa.